[1]樊 蓓,刘 倩.不同剂量利伐沙班治疗老年心力衰竭合并房颤患者的临床效果及安全性对比[J].医学信息,2025,38(13):142-145.[doi:10.3969/j.issn.1006-1959.2025.13.028]
　FAN Bei,LIU Qian.Comparison of Clinical Efficacy and Safety of Different Doses of Rivaroxaban in the Treatmentof Elderly Patients with Heart Failure and Atrial Fibrillation[J].Journal of Medical Information,2025,38(13):142-145.[doi:10.3969/j.issn.1006-1959.2025.13.028]
点击复制

不同剂量利伐沙班治疗老年心力衰竭合并房颤患者的临床效果及安全性对比()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年13期
页码:
142-145
栏目:
论著
出版日期:
2025-07-01

文章信息/Info

Title:
Comparison of Clinical Efficacy and Safety of Different Doses of Rivaroxaban in the Treatmentof Elderly Patients with Heart Failure and Atrial Fibrillation
文章编号:
1006-1959（2025）13-0142-04
作者:
樊 蓓; 刘 倩
西安市高陵区中医医院药剂科，陕西 西安 710200
Author(s):
FAN Bei;  LIU Qian
Department of Pharmacy, Gaoling District Hospital of Traditional Chinese Medicine, Xi’an 710200, Shaanxi, China
关键词:
不同剂量; 利伐沙班; 老年; 心力衰竭; 房颤; 安全性
Keywords:
Different doses;  Rivaroxaban;  Elderly;  Heart failure;  Atrial fibrillation;  Safety
分类号:
R541.6；R541.7+5
DOI:
10.3969/j.issn.1006-1959.2025.13.028
文献标志码:
A
摘要:
目的 研究不同剂量利伐沙班治疗老年心力衰竭合并房颤患者的临床效果及安全性。方法 采用随机数字表法将2022年4月-2023年4月在我院诊治的58例老年心力衰竭合并房颤患者分为对照组和观察组，各29例。对照组利伐沙班治疗剂量为20 mg/d，观察组利伐沙班治疗剂量为10 mg/d，比较两组临床疗效、心功能指标、凝血功能指标、不良反应发生率、心脑血管事件发生率。结果 两组治疗总有效率比较无统计学差异（P＞0.05）；两组左室射血分数（LVEF）均高于治疗前，舒张末期左心室后壁厚度（LVPWD）均低于治疗前（P＜0.05），但两组治疗后LVEF、LVPWD比较无统计学差异（P＞0.05）；两组D-二聚体（D-D）均低于治疗前，凝血酶原时间（PT）均高于治疗前（P＜0.05），但两组D-D、PT比较无统计学差异（P＞0.05）；观察组不良反应发生率及心脑血管事件发生率均低于对照组（P＜0.05）。结论 不同剂量利伐沙班治疗老年心力衰竭合并房颤患者临床效果基本一致，均可改善心功能指标、凝血功能指标，但10 mg/d利伐沙班不良反应少，心脑血管事件发生率低，具有相对更优的治疗安全性。
Abstract:
Objective To study the clinical effect and safety of different doses of rivaroxaban in the treatment of elderly patients with heart failure and atrial fibrillation. Methods From April 2022 to April 2023, 58 elderly patients with heart failure complicated by atrial fibrillation treated in our hospital were divided into a control group and an observation group (29 cases per group) using a random number table method. The control group received rivaroxaban with a dose of 20 mg/d, while the observation group received rivaroxaban with a dose of 10 mg/d. The clinical efficacy, cardiac function index, coagulation function index, incidence of adverse reactions and incidence of cardiovascular and cerebrovascular events were compared between the two groups. Results There was no statistically significant difference in the total effective rate of treatment between the two groups(P>0.05). The left ventricular ejection fraction (LVEF) of the two groups was higher than that before treatment, and the end-diastolic left ventricular posterior wall thickness (LVPWD) was lower than that before treatment (P<0.05), but there was no statistically significant difference in LVEF and LVPWD between the two groups after treatment (P>0.05). The D-dimer (D-D) of the two groups was lower than that before treatment, and the prothrombin time (PT) was higher than that before treatment (P<0.05), but there was no statistically significant difference in D-D and PT between the two groups after treatment (P>0.05). The incidences of adverse reactions and cardiovascular and cerebrovascular events in the observation group were both lower than those in the control group (P<0.05). Conclusion The clinical effects of different doses of rivaroxaban in the treatment of elderly patients with heart failure and atrial fibrillation are basically the same, which can improve cardiac function indexes and coagulation function indexes. However, 10 mg/d rivaroxaban has fewer adverse reactions and lower incidence of cardiovascular and cerebrovascular events, and has relatively better treatment safety.

参考文献/References:

[1]陈永刚,王红卫,许莹.利伐沙班对稳定性冠心病合并房颤患者临床疗效及脑血管意外事件发生率的影响研究[J].贵州医药,2021,45(5):759-761.[2]段靳岚,穆宁晖.新型口服抗凝药物利伐沙班在老年稳定性冠心病合并心房颤动患者中的应用价值研究[J].实用心脑肺血管病杂志,2021,29(7):51-56.[3]赵冬梅,赵兴胜,南景龙.利伐沙班联合氯吡格雷对房颤合并冠心病行经皮冠脉介入术患者的疗效观察[J].中国药师,2020,23(8):1566-1569.[4]周小俊,宋雨,王涛.参松养心胶囊对老年心力衰竭合并房颤患者心室重构、NT-proBNP及QTd的影响[J].老年医学与保健,2023,29(3):502-505,518.[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.冠心病合并心房颤动患者抗栓管理中国专家共识[J].中华心血管病杂志,2020,48(7):552-564.[6]李文,董星彤,贾强,等.服用利伐沙班是冠心病或非瓣膜性房颤患者发生急性肾脏病的危险因素[J].中华肾脏病杂志,2020,36(10):744-749.[7]袁森,闫洁.倍他乐克联合贝那普利治疗老年慢性稳定性心力衰竭的疗效及对患者心室重塑的影响[J].海南医学,2021,32(5):563-566.[8]Chan YH,See LC,Tu HT,et al.Efficacy and safety of apixaban,dabigatran,rivaroxaban,and warfarin in Asians with nonvalvular atrial fibrillation[J].J Am Heart Assoc,2018,7(8):e008150.[9]江丽华,黄嘉利,陈丽华.利伐沙班用于非瓣膜性心房颤动患者抗凝治疗的疗效及安全性[J].中国医院用药评价与分析,2019,19(3):304-305.[10]侯玉玲.小剂量地高辛联合美托洛尔治疗慢性心力衰竭伴快室率房颤的疗效观察[J].现代诊断与治疗,2019,30(2):268-269.[11]许宇文,刘琼,沈琼,等.利伐沙班在高龄心力衰竭合并房颤抗凝治疗中的剂量优化研究[J].实用老年医学,2022,10(10):1028-1030.[12]梅迎丽.胺碘酮联合琥珀酸美托洛尔治疗慢性心力衰竭合并快室率房颤的临床疗效[J].中国处方药,2018,16(6):55-56.[13]张铁峰.胺碘酮联合美托洛尔治疗快室率房颤伴心力衰竭的疗效观察[J].山西职工医学院学报,2017,27(5):25-27.[14]王倩,张丽,黄俊,等.利伐沙班在高龄非瓣膜性心房颤动患者中的常用剂量及预后分析[J].岭南心血管病杂志,2019,25(6):638-641.[15]禹越,杨伟,杜彬,等.10 mg/d与15 mg/d利伐沙班在75岁及以上非瓣膜性心房颤动患者中的应用[J].中国分子心脏病学杂志,2024,24(2):5964-5969.[16]Wysokinski WE,Houghton DE,Casanegra AI,et al.Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism[J].Am J Hematol,2019,94(11):1185-1192.[17]李茜,严思敏,葛卫红,等.不同剂量利伐沙班对非瓣膜性房颤患者血栓栓塞与出血事件影响的研究[J].中南药学,2021,19(3):534-538.[18]艾阳,李必龙,朱春甲,等.低剂量利伐沙班在老年非瓣膜性房颤治疗中的效果观察[J].实用老年医学,2020,34(7):666-669.[19]秦瑜霜.利伐沙班对稳定性冠心病合并心房颤动患者临床疗效及生活质量的影响分析[J].心血管病防治知识,2021,30(11):13-15.[20]王葛,赵力,张博阳,等.心功能对非瓣膜性心房颤动合并冠状动脉支架植入患者缺血性脑卒中及死亡风险的影响[J].中国全科医学,2019,22(10):1176-1181.[21]赵小奎,孙玉梅,杨莉.阿哌沙班与利伐沙班用于心衰合并房颤抗凝治疗的效果对比[J].解放军预防医学杂志,2019,37(2):163-164.

相似文献/References:

[1]李凤利,陈 伟,张 林.不同剂量沐舒坦在肺癌围术期的肺功能保护作用[J].医学信息,2018,31(07):128.[doi:10.3969/j.issn.1006-1959.2018.07.043]
　LI Feng-li,CHEN Wei,ZHANG Lin.Protective Effects of Different Doses of Ambroxol on Lung Function in Patients with Lung Cancer during Perioperative Period[J].Journal of Medical Information,2018,31(13):128.[doi:10.3969/j.issn.1006-1959.2018.07.043]
[2]庞永华,陈伟南,许科峰,等.TKA应用氨甲环酸后序贯应用两种新型口服抗凝药预防VTE的疗效对比[J].医学信息,2022,35(09):100.[doi:10.3969/j.issn.1006-1959.2022.09.025]
　PANG Yong-hua,CHEN Wei-nan,XU Ke-feng,et al.Comparison of Efficacy of Sequential Application of Two New Oral Anticoagulants in the Prevention of VTE After Application of Tranexamic Acid in TKA[J].Journal of Medical Information,2022,35(13):100.[doi:10.3969/j.issn.1006-1959.2022.09.025]
[3]杨利中,冯欢欢,刘 华,等.桃红四物汤联合氨甲环酸对人工股骨头置换术后 隐形失血的影响[J].医学信息,2019,32(17):150.[doi:10.3969/j.issn.1006-1959.2019.17.050]
　YANG Li-zhong,FENG Huan-huan,LIU Hua,et al.Effect of Taohong Siwu Decoction Combined with Tranexamic Acid on Invisible Blood Loss after Artificial Femoral Head Replacement[J].Journal of Medical Information,2019,32(13):150.[doi:10.3969/j.issn.1006-1959.2019.17.050]
[4]花国辉.不同剂量阿托伐他汀治疗心梗后无症状心衰的疗效比较[J].医学信息,2020,33(04):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
　HUA Guo-hui.Comparison of the Effects of Different Doses of Atorvastatin on Asymptomatic Heart Failure After Myocardial Infarction[J].Journal of Medical Information,2020,33(13):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
[5]蔡庆宇,刘海洲.利伐沙班和低分子肝素钙预防中重度脑出血术后下肢深静脉血栓形成的效果比较[J].医学信息,2021,34(08):150.[doi:10.3969/j.issn.1006-1959.2021.08.040]
　CAI Qing-yu,LIU Hai-zhou.Comparison of the Effects of Rivaroxaban and Low-molecular-weight Heparin Calcium in Preventing Deep Vein Thrombosis of Lower Extremities After Moderate to Severe Intracerebral Hemorrhage[J].Journal of Medical Information,2021,34(13):150.[doi:10.3969/j.issn.1006-1959.2021.08.040]
[6]李杨华.不同剂量瑞芬太尼用于无痛胃镜检查的有效性及安全性[J].医学信息,2024,37(23):54.[doi:10.3969/j.issn.1006-1959.2024.23.012]
　LI Yanghua.Efficacy and Safety of Different Doses of Remifentanil for Painless Gastroscopy[J].Journal of Medical Information,2024,37(13):54.[doi:10.3969/j.issn.1006-1959.2024.23.012]
[7]陈 添.不同剂量布地奈德雾化吸入对老年慢性阻塞性肺病急性加重期患者的治疗效果观察[J].医学信息,2025,38(13):98.[doi:10.3969/j.issn.1006-1959.2025.13.018]
　CHEN Tian.Observation on the Therapeutic Effect of Different Doses of Budesonide for Aerosol Inhalationon Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(13):98.[doi:10.3969/j.issn.1006-1959.2025.13.018]
[8]李 星,齐海超,赵 翟.炙甘草汤加减联合利伐沙班治疗脑梗死并房颤的临床疗效及对其神经功能的影响[J].医学信息,2025,38(14):103.[doi:10.3969/j.issn.1006-1959.2025.14.019]
　LI Xing,QI Haichao,ZHAO Zhai.Clinical Efficacy of Modified Zhigancao Decoction Combined with Rivaroxaban in the Treatment of Cerebral Infarction Complicated with Atrial Fibrillation and its Effect on Neurological Function[J].Journal of Medical Information,2025,38(13):103.[doi:10.3969/j.issn.1006-1959.2025.14.019]

更新日期/Last Update: 1900-01-01